This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / SkylineDx Launches Merlin CP-GEP Test
Business product launch

SkylineDx Launches Merlin CP-GEP Test

Analysis based on 11 articles · First reported Feb 19, 2026 · Last updated Mar 05, 2026

Sentiment
60
Attention
4
Articles
11
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The launch of SkylineDx's Guideline-Informed Risk Assessment Initiative and Merlin CP-GEP test is expected to positively impact the biotechnology and healthcare markets by providing a guideline-recognized tool for melanoma risk assessment. This could lead to increased adoption of advanced molecular diagnostics and improved patient outcomes, potentially boosting SkylineDx's market share.

Biotechnology Healthcare Medical Diagnostics
Event Summary

SkylineDx announced the launch of its Guideline-Informed Risk Assessment Initiative and the Merlin CP-GEP test on March 5, 2026. This clinical program aims to support surgeons and multidisciplinary teams in evaluating T1 and T2 melanoma patients by providing a predictive molecular test for individualized SLN metastasis risk. The initiative aligns with the updated NCCN Guidelines, which now state that CP-GEP testing may be used in select patients to support shared decision-making. Merlin CP-GEP is the only gene expression profile assay prospectively validated for assessing metastatic potential and SLN positivity risk, distinguishing it from 'Alternative GEP' assays not recommended by current guidelines. The test, co-developed by SkylineDx and Mayo Clinic, is available in the United States and Europe, and is expected to enhance precision in early-stage melanoma care.

Key Actions
100 SkylineDx launched Guideline-Informed Risk Assessment Initiative and Merlin CP-GEP test
85 National Comprehensive Cancer Network updated guidelines to recognize CP-GEP testing SkylineDx
40 Mayo Clinic co-developed CP-GEP model SkylineDx
Entities Involved
priv
SkylineDx
SkylineDx launched the Guideline-Informed Risk Assessment Initiative and the Merlin CP-GEP test, which is expected to increase its market presence and revenue in the oncology diagnostics sector. This initiative aligns with updated NCCN Guidelines, enhancing the credibility and adoption of their product.
Importance 100 Sentiment 75
ngo
National Comprehensive Cancer Network
The National Comprehensive Cancer Network's updated guidelines recognize CP-GEP testing, which directly supports the adoption and clinical utility of SkylineDx's Merlin CP-GEP test.
Importance 80 Sentiment 50
per
Dharminder Chahal
As CEO of SkylineDx, Dharminder Chahal's statements highlight the company's strategic direction towards more precise, guideline-aligned care in melanoma, reinforcing the importance of the new initiative.
Importance 70 Sentiment 60
ngo
Mayo Clinic
Mayo Clinic co-developed the advanced CP-GEP model with SkylineDx, lending scientific credibility to the Merlin CP-GEP test.
Importance 40 Sentiment 50
cnt
United States
The United States is a key market for the Merlin CP-GEP test, with approximately 35,000 patients diagnosed with T1b and T2a melanoma annually, indicating a significant potential user base for the new initiative.
Importance 20 Sentiment 0
loc
Europe
The Merlin CP-GEP test has also been launched in Europe, indicating SkylineDx's broader market strategy beyond the United States.
Importance 10 Sentiment 0
Relationships
SkylineDx related ↔ Mayo Clinic
Dharminder Chahal related ↔ SkylineDx
SkylineDx related ↔ National Comprehensive Cancer Network
Dharminder Chahal related ↔ National Comprehensive Cancer Network
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.